Diagnosis and Treatment of Hemophilia

Dear Colleagues,

Over the past 30 years, the diagnosis and treatment of patients with hemophilia A and B has improved considerably. In recent years, the implementation of new technologies, such as next-generation sequencing or droplet PCR, has modernized the detection of genetic defects in hemophilia patients and in female relatives who might be carriers. Prenatal diagnosis has also significantly progressed during the last two decades. Non-invasive methods have replaced invasive procedures, and preimplantation genetic testing (PGT) has become an important complement to the approaches currently available in the prevention of genetic diseases.

At present, patients with hemophilia A and B can choose different effective and safe treatments, including novel extended-half-life products, non-replacement therapies, and even gene therapy. The shift from standard FVIII and FIX concentrates to the extended-half-life products has significantly changed the management of hemophilia patients, making treatment less distressing and improving their quality of life. Subcutaneous administration of non-replacement therapies such as emicizumab have simplified prophylaxis in patients with hemophilia A with and without inhibitors. In addition, gene therapy is becoming a promising therapeutic choice.

With this background, this Special Issue will try to highlight how new diagnostic and therapeutic approaches have advanced to improve patients' quality of life.

Prof. Flora Peyvandi
Dr. Isabella Garagiola
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.